PXMD.US PaxMedica, Inc. Common Stock

Healthcare Biotechnology USA Stocks
0.0005 USD
Close of Nov 18, 2026
Market cap
USD 63.1K
P/E
-
P/B
0.98x
ROE
-
Dividend yield
18,922,156.76%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.

Is PXMD.US undervalued?

Graham number

The Graham number of PaxMedica, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PaxMedica, Inc. Common Stock fundamental analysis

No fundamental analysis for PaxMedica, Inc. Common Stock yet.

PaxMedica, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PaxMedica, Inc. Common Stock

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HA…

Full company profile